Imaging of Pulmonary Vascular Disease.

Radiol Clin North Am

Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address:

Published: March 2025

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rcl.2024.09.006DOI Listing

Publication Analysis

Top Keywords

imaging pulmonary
4
pulmonary vascular
4
vascular disease
4
imaging
1
vascular
1
disease
1

Similar Publications

Background: Diaphragm thickness is a potential marker of sarcopenia in addition to muscle mass and strength at extremities. We aimed to clarify the descriptive epidemiology and prognostic significance of diaphragm thickness in the general population.

Methods: The study participants were 3324 community residents (mean age: 61.

View Article and Find Full Text PDF

Background: Ultrasound lung surface motion measurement is valuable for the evaluation of a variety of diseases. Speckle tracking or Doppler-based techniques are limited by the loss of visualization as a tracked point moves under ribs or is dependent.

Methods: We developed a synthetic lateral phase-based algorithm for tracking lung motion to overcome these limitations.

View Article and Find Full Text PDF

Background: Dermatomyositis is a chronic inflammatory condition affecting muscles and skin, often associated with an increased risk of cancer. Specific autoantibodies, including anti-TIF1 (Transcription Intermediary Factor 1), have been linked to this risk. We present a case of dermatomyositis in a male patient positive for anti-TIF1 antibodies, subsequently diagnosed with squamous cell carcinoma of the tonsil, a novel association not previously documented.

View Article and Find Full Text PDF

Longitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases.

Sci Rep

January 2025

Department of Radiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, Hubei, China.

Brain metastases (BM) are the most prevalent intracranial malignancies. Approximately 30-40% of cancer patients develop BM at some stage of their illness, presenting with a high incidence and poor prognosis. Our clinical findings indicate a significant disparity in the efficacy between non-enhanced and enhanced lung cancer BM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!